Sudan and South Sudan Pharmaceuticals and Healthcare Report Q1 2013

  • ID: 2372978
  • January 2013
  • Region: Sudan
  • 40 pages
  • Business Monitor International
1 of 3

BMI View:

Sudan and South Sudan's will continue to be of least interest to foreign pharmaceutical firms in the Middle East and North Africa region as the countries are plagued by high inflation, fiscal constraints and underdeveloped non-oil economies. Political risk remains elevated as many disputes between them are still unresolved. These macroeconomic uncertainties will mean lack of focus on public healthcare provision, which further complicates the problem that the general population are unable to afford expensive pharmaceuticals.

Headline Expenditure Projections:

- Pharmaceuticals: SDG1.49bn (US$556mn) in 2011 to SDG1.93bn (US$472mn) in 2012;
30.0% in local currency terms with a contraction of 15.1% in US dollar terms. Forecast unchanged from Q412.

- Healthcare: SDG11.01bn (US$4.12mn) in 2011 to SDG13.44bn (US$3.29bn) in 2012; +22.0
%in local currency terms and -20% in US dollar terms. Forecast down slightly from Q412's, due to reassessment of historic values.

Risk/Reward Ratings:

BMI rates Sudan as the most unattractive market in the Middle East and Africa
(MEA) region, highlighted by its score of 20.8 out of 100. With the exception READ MORE >

Note: Product cover images may vary from those shown
2 of 3

BMI Industry View 5

Pharmaceutical Risk/Reward Ratings 7
Table: Middle East and Africa - Q113 Risk-Reward Ratings Matrix 7

Sudan Languishes In MEA Risk/Reward Ratings 10

Rewards 11

Risks 11

Market Summary 12

Regulatory Regime 14

Industry Forecast Scenario 15

Assessing The Value Of Sudan And South Sudan's Pharmaceutical Market 15

Pharmaceutical Market Forecast 17
Table: Pharmaceutical Sales Indicators, 2008-2016 19

Industry Developments 20

Healthcare Market Forecast 21
Table: Healthcare Expenditure Indicators, 2008-2016 23
Table: Healthcare Governmental Indicators, 2008-2016 24
Table: Healthcare Private Indicators, 2008-2016 25

Key Growth Factors - Macroeconomic 25

Demographic Outlook 30
Table: Sudan's Population By Age Group, 1990-2020 ('000) 31
Table: Sudan's Population By Age Group, 1990-2020 (% of total) 32
Table: Sudan's Key Population Ratios, 1990-2020 33
Table: Sudan's Rural And Urban Population, 1990-2020 33

Glossary 34

BMI Methodology 36

How We Generate Our Pharmaceutical Industry Forecasts 36

Pharmaceuticals Business Environment Ratings 37

Risk/Reward Ratings Methodology 37

Ratings Overview 37
Table: Pharmaceutical Business Environment Indicators 38

Weighting 39
Table: Weighting Of Components 39

Sources 39

Note: Product cover images may vary from those shown
3 of 3
Note: Product cover images may vary from those shown


  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.


If you have a more general question about our products please try our



Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.